ProCE Banner Activity

Rationale for Targeting CD38, Disparities in Care, and Treatment Implications in Newly Diagnosed MM


Download these slides for an overview of the rationale for targeting CD38 in MM, as well as a review of disparities in care and considerations with new data. 

Released: June 10, 2024

Expiration: June 09, 2025



Paul G. Richardson

Paul G. Richardson, MD

Director of Clinical Research
Clinical Program Leader
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Sanofi.